companydata.dkcompanydata.dk

AGC Biologics A/S: Financial statements 2025

CVR: 25950941

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

AGC Biologics A/S (CVR 25950941) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. That is a decrease of 2.8% compared with the year before. The profit margin was -16.7%. Equity in the 2025 report amounted to DKK 312,021,000. The solvency ratio was 7.7%. The company had 1,138 employees in the financial year.

Revenue
DKK 1,959,639,000
Gross Profit
DKK -91,242,000
Profit/Loss
DKK -328,010,000
Equity
DKK 312,021,000
Total Assets
DKK 4,050,883,000
Employees
1,138

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
20252B-91.2M-328M312M1138
20242B160.2M-115M640M1019
20232.1B501.3M243.9M307.4M956
20222.5B937M598.9M661.3M894
20212.2B831.9M571.7M633.6M730

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is AGC Biologics A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

AGC Biologics A/S: The 2024 annual report is outJul 11, 2025

AGC Biologics A/S has published its annual report for 2024. Revenue came to DKK 2,016,194,000, and the net result was DKK -115,005,000.

Kasper Møller joins AGC Biologics A/S as adm. dir.Apr 1, 2025

As of April 1, 2025, Kasper Møller is registered as adm. dir. of AGC Biologics A/S.

Andrea Celia Porchia steps down as adm. dir. of AGC Biologics A/SApr 1, 2025

As of April 1, 2025, Andrea Celia Porchia has stepped down as adm. dir. of AGC Biologics A/S.

Alberto Santagostino joins the board of AGC Biologics A/SMar 3, 2025

As of March 3, 2025, Alberto Santagostino has joined the board of directors of AGC Biologics A/S.

Mai Iwaya joins the board of AGC Biologics A/SMar 3, 2025

As of March 3, 2025, Mai Iwaya has joined the board of directors of AGC Biologics A/S.

Akira Nakamura leaves the board of AGC Biologics A/SMar 3, 2025

As of March 3, 2025, Akira Nakamura has left the board of directors of AGC Biologics A/S.

About AGC Biologics A/S

AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,503 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.

Source: annual report 2025, Danish Business Authority